We analyzed DC1 (MHCII+CD11c+Xcr1+) and DC2 (MHCII+CD11c+CD172+) subtypes within the primary (tumor) and secondary (draining lymph node [dLN]) sites of tumor immunity (gating scheme is shown in Supplemental Figure 2A) of tumor-bearing mice 3 weeks after implantation. This evidence concerns the gene XCR1 and neoplasm.